← GIP/GLP-1 & amylin agonists × adverse events & safety

SynthesisThe Cochrane database of systematic reviews2025

Tirzepatide for adults living with obesity.

Juan Va Franco et al.PubMed ↗Full text ↗Publisher ↗

  • Tirzepatidecuts both waysLower percentage reduction in body weight, more non-serious adverse events, higher adverse events leading to withdrawal.Randomised, large.

What the trial testedrandomised · 7,111 people · 2025

Randomised vs placebo

Lowered percentage reduction in body weight

−16.0−18.9 to −13.1

tirzepatide vs placebo

As reported

difference −16.03, 95% CI −18.9 to −13.1 · the paper's word: percentage reduction in body weight from baseline

Randomised comparison

Raised body weight & composition

3.6×2.4× to 5.3×

Bigger than 9 in 10 on the map

As reported

RR 3.60, 95% CI 2.44–5.30

Randomised vs placebo

Increased non-serious adverse events

+33%+3% to +71%

tirzepatide vs placebo

Bigger than 6 in 10 for adverse events & safety

As reported

RR 1.33, 95% CI 1.03–1.71

Randomised vs placebo

Raised adverse events leading to withdrawal

2.1×1.2× to 3.5×

tirzepatide vs placebo

Bigger than 8 in 10 for adverse events & safety

As reported

RR 2.06, 95% CI 1.21–3.52

+6 more in the walkthrough ↓

Who was studied, and how

7,111people with obesity, in this paper

The trial randomly assignedassigned by chance

tirzepatide
placebo

Lowered percentage reduction in body weight−16.0

Increased non-serious adverse events+33%

Raised adverse events leading to withdrawal2.1×

randomised

the abstract, start to end

… from baseline (mean difference (MD) -16.03, 95% confidence interval (CI) -18.91 to -13.14; 8 studies, 6317 participants; moderate-certainty evidence), and an increase in the number of people achieving a 5% weight reduction (risk ratio (RR) 3.60, 95% CI 2.44 to 5.30; I2 = 86%; …

… in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 …

… the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 …

… adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 …

… in little to no difference in MACE (RR 0.75, 95% CI 0.34 to 1.66; I² = 0%; …

… physical function domain (MD 9.91, 95% CI 7.81 to 12.02; 6 …

… little to no difference in mortality (RR 0.79, 95% CI 0.34 to 1.83; 7 …

… in body weight from baseline (MD -15.66, 95% CI -19.14 to -12.18; 1 study, 1032 participants; moderate-certainty evidence), and an increase in the number of people achieving a 5% weight reduction (RR 2.81, 95% CI 2.33 to 3.38; 1 study, …

← favours treatmentfavours comparator →
could be chance
Percentage reduction in body weight from baselinetirzepatide vs placebo
−16.03−18.9 to −13.1
Body weight & composition
RR 3.602.44–5.30
Non-serious adverse eventstirzepatide vs placebo
RR 1.331.03–1.71
Serious adverse eventstirzepatide vs placebo
RR 0.990.88–1.12
Adverse events leading to withdrawaltirzepatide vs placebo
RR 2.061.21–3.52
Major adverse cardiovascular events (MACE)tirzepatide vs placebo
RR 0.750.34–1.66
Quality of life as measured by the IWQOL-Lite-CT physical function domaintirzepatide vs placebo
9.917.81–12.0
Mortalitytirzepatide vs placebo
RR 0.790.34–1.83
Percentage reduction in body weight from baselinetirzepatide vs placebo
−15.66−19.1 to −12.2
Body weight & composition
RR 2.812.33–3.38
GIP/GLP-1 & amylin agonistsBody weight & compositionCardiovascular eventsAll-cause mortalityAdverse events & safetyQuality of life & behaviour

GIP/GLP-1 & amylin agonists × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.00not counted

GIP/GLP-1 & amylin agonists × all-cause mortalityhelps?one trial

unlikelylikely
0.35not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

3 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 41161687